No Data
No Data
Zhejiang Jianfeng's Pharmaceutical Unit Gets Nod to Market Anti-Tumor Drug
China's National Medical Products Administration approved the application of Zhejiang Jianfeng Group's (SHA:600668) unit, Jianfeng Pharmaceutical, to register raw drug ingredient imatinib mesylate for
Zhejiang Huakang Pharmaceutical Co., Ltd.'s (SHSE:605077) 7.7% Gain Last Week Benefited Both Retail Investors Who Own 43% as Well as Insiders
Key Insights The considerable ownership by retail investors in Zhejiang Huakang Pharmaceutical indicates that they collectively have a greater say in management and business strategy The top 12 shar
Zhejiang XCC Group Co.,Ltd's (SHSE:603667) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?
Zhejiang XCC GroupLtd's (SHSE:603667) stock is up by a considerable 26% over the past three months. We wonder if and what role the company's financials play in that price change as a company's long-
Are Investors Undervaluing Zhejiang Taihua New Material Co.,Ltd (SHSE:603055) By 38%?
Key Insights Zhejiang Taihua New MaterialLtd's estimated fair value is CN¥20.53 based on 2 Stage Free Cash Flow to Equity Zhejiang Taihua New MaterialLtd is estimated to be 38% undervalued based on
Returns At Zhejiang Zomax Transmission (SHSE:603767) Are On The Way Up
What are the early trends we should look for to identify a stock that could multiply in value over the long term? Firstly, we'd want to identify a growing return on capital employed (ROCE) and then a
Zhejiang Daily Digital Culture GroupLtd's (SHSE:600633) Three-year Total Shareholder Returns Outpace the Underlying Earnings Growth
One simple way to benefit from the stock market is to buy an index fund. But if you choose individual stocks with prowess, you can make superior returns. For example, the Zhejiang Daily Digital Cult
No Data